Keting Chu
Algemeen Directeur bij Bluejay Therapeutics, Inc.
Profiel
Keting Chu is the founder of Bluejay Therapeutics, Inc. She previously worked as a Director at TempestTx, Inc.
Actieve functies van Keting Chu
Bedrijven | Functie | Begin |
---|---|---|
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Algemeen Directeur | - |
Eerdere bekende functies van Keting Chu
Bedrijven | Functie | Einde |
---|---|---|
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients. | Commercial Services |